Galunisertib During Normothermic Machine Perfusion Attenuates Profibrotic Signaling in Discarded Human Donor Kidneys

INTRODUCTION: Early-onset fibrosis limits kidney transplant success, causing early allograft failure in up to 50% of deceased donor kidneys within 10 years or excluding many from transplantation. Normothermic machine perfusion (NMP) offers a platform for targeted drug delivery to isolated organs, minimizing systemic effects. This study evaluated whether galunisertib modulates fibrosis-associated molecular signaling when administered to discarded human kidneys during ex vivo NMP, while assessing treatment safety and pharmacokinetics. METHODS: Twelve discarded human kidneys underwent 4 h of oxygenated hypothermic perfusion followed by 6 h of NMP with galunisertib or vehicle (n = 6). Precision-cut kidney slices (PCKS) were then cultured for 48 h with either continued or discontinued galunisertib exposure. Endpoints included fibrosis-related mRNA expression and pharmacokinetics. RESULTS: Galunisertib was administered during NMP and steadily excreted in urine without adverse effects on organ function. Continued exposure in PCKS significantly attenuated fibrosis-related mRNA expression, including SERPINE1 (24 h: p = 0.0057; 48 h: p = 0.0046). Discontinuation increased ACTA2 expression (p = 0.0156), while continued treatment prevented this phenomenon (p = 0.0014). CONCLUSION: NMP enabled targeted delivery of galunisertib to discarded human kidneys without detectable adverse effects on ex vivo renal function. Prolonged galunisertib exposure was associated with modest attenuation of fibrosis-associated molecular markers during subsequent tissue culture. These findings provide proof-of-concept for pharmacological modulation of profibrotic signaling during ex vivo kidney perfusion.

Authors

Institutions

Publication Details

Journal
Artificial Organs
Published
2026-11-18
DOI
https://doi.org/10.1111/aor.70281
Primary Topic
Organ Transplantation Techniques and Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Galunisertib During Normothermic Machine Perfusion Attenuates Profibrotic Signaling in Discarded Human Donor Kidneys

Henri G. D. Leuvenink, Daan Johannes Touw, Petra J. Ottens, Cyril Moers et al.
2 links
Artificial Organs
Organ Transplantation Techniques and Outcomes
article

Galunisertib During Normothermic Machine Perfusion Attenuates Profibrotic Signaling in Discarded Human Donor Kidneys

Henri G. D. Leuvenink, Daan Johannes Touw, Petra J. Ottens, Cyril Moers, Peter Olinga, Baran Ogurlu, Christopher L. Jaynes, Veerle A. Lantinga, Carolina Campos Pamplona, Tim L. Hamelink, L. Leonie van Leeuwen, Kai van Hateren, Jan‐Luuk Hillebrands, Cristina Ballester Bergada
article en

Abstract

INTRODUCTION: Early-onset fibrosis limits kidney transplant success, causing early allograft failure in up to 50% of deceased donor kidneys within 10 years or excluding many from transplantation. Normothermic machine perfusion (NMP) offers a platform for targeted drug delivery to isolated organs, minimizing systemic effects. This study evaluated whether galunisertib modulates fibrosis-associated molecular signaling when administered to discarded human kidneys during ex vivo NMP, while assessing treatment safety and pharmacokinetics. METHODS: Twelve discarded human kidneys underwent 4 h of oxygenated hypothermic perfusion followed by 6 h of NMP with galunisertib or vehicle (n = 6). Precision-cut kidney slices (PCKS) were then cultured for 48 h with either continued or discontinued galunisertib exposure. Endpoints included fibrosis-related mRNA expression and pharmacokinetics. RESULTS: Galunisertib was administered during NMP and steadily excreted in urine without adverse effects on organ function. Continued exposure in PCKS significantly attenuated fibrosis-related mRNA expression, including SERPINE1 (24 h: p = 0.0057; 48 h: p = 0.0046). Discontinuation increased ACTA2 expression (p = 0.0156), while continued treatment prevented this phenomenon (p = 0.0014). CONCLUSION: NMP enabled targeted delivery of galunisertib to discarded human kidneys without detectable adverse effects on ex vivo renal function. Prolonged galunisertib exposure was associated with modest attenuation of fibrosis-associated molecular markers during subsequent tissue culture. These findings provide proof-of-concept for pharmacological modulation of profibrotic signaling during ex vivo kidney perfusion.

Artificial Organs
Mount Sinai Hospital (US), University Medical Center Groningen (NL), University of Groningen (NL), Aarhus University Hospital (DK), Icahn School of Medicine at Mount Sinai (US)
Good health and well-being
Organ Transplantation Techniques and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon